BioSpace News Archive

Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today reported select preliminary, unaudited financial results for the fourth quarter and full-year 2020. In addition, the Company highlighted its key 2021 corporate objectives.

Antares Pharma, Inc., a pharmaceutical technology company, announced guidance for full-year 2021 and expects revenue to be in a range of $175 to $200 million, which assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the H.C. Wainwright BioConnect 2021 Virtual Conference.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the completion of patient enrollment in the INFINITY Phase 2 trial to evaluate a single intravitreal injection of ADVM-022, for the treatment of diabetic macular edema (DME)

Bioheart comfortably and continuously monitors daily activities and provides advanced heart performance data in a user-friendly format

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today provided an operational update and announced its 2021 objectives.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to highlight an independent research review (the “Review”) published in the January 5th edition of the European Archives of Psychiatry and Clinical Neuroscience, that identified Ifenprodil as a possible re-purposed drug candidate for the treatment of COVID-19.

InterShunt Technologies, Inc., an early-stage medical device company developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients, announced the completion of an equity financing.

A study described in a letter to the editor in the January issue of Mayo Clinic Proceedings entitled “Aseptic Disposable Stethoscope Barrier: Acoustically Invisible and Superior to Disposable Stethoscopes"1 found that aseptic disk cover barriers from AseptiScope (www.diskcover.com),

OncoHost, global leader in host response profiling for improved personalized cancer therapy, announced today that renowned biologist and winner of The Nobel Prize in Chemistry, Professor Aaron Ciechanover, has joined the company’s scientific advisory board.